Botox
onabotulinumtoxinA
APPROVED
Drug Profile
ModalityBiologic
RouteInjection
Therapy AreaNeurology
Launch1989-12-29
US LOE2030-01-01
Peak Sales Est$5000M
Formulations[{"id":"botox-inj","route":"IM","setting":"OFFICE","frequency":"Every 12 weeks (chronic migraine)","
Mechanism: Botulinum neurotoxin
Expert: Clostridium botulinum type A neurotoxin that cleaves SNAP-25, blocking acetylcholine release at neuromuscular junctions.
Everyday: A purified protein that temporarily relaxes muscles by blocking nerve signals.
Targets: []
Revenue History
| Period | Revenue ($M) |
|---|
| 2024 | $3,281M |
| 2025 | $3,769M |
| Q4 2025 | $980M |
Programs (2)
| Indication | Stage | Key Study | Regional Status |
|---|
| Chr Migraine | APPROVED | PREEMPT | [{"stage":"APPROVED","region":"US","approval_date":"2010-10-15"}] |
| UL Spasticity | APPROVED | Phase 3 spasticity | [{"stage":"APPROVED","region":"US","approval_date":"2010-10-01"}] |
Notes
Market leader in therapeutic and cosmetic applications. Therapeutic: chronic migraine, spasticity, overactive bladder. 2025 therapeutic revenue $3.8B. Cosmetic revenue $2.6B (separate franchise).
Data from Supabase · Updated 2026-03-24